579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Petrylak, DP; Perez-Gracia, JL; Lacombe, L; Bastos, DA; Mahammedi, H; Kwan, EM; Zschäbitz, S; Armstrong, AJ; Pachynski, RK; Goh, JC; Burotto, M; Gravis, G; McCune, SL; Vázquez Limón, JC; Retz, M; Saad, F; Amin, NP; Li, J; Unsal-Kacmaz, K; Fizazi, K

Published Date

  • September 2021

Published In

Volume / Issue

  • 32 /

Start / End Page

  • S629 - S630

Published By

International Standard Serial Number (ISSN)

  • 0923-7534

Digital Object Identifier (DOI)

  • 10.1016/j.annonc.2021.08.1092